Charles River Laboratories (CRL) Stock Forecast, Price Target & Predictions
CRL Stock Forecast
Charles River Laboratories stock forecast is as follows: an average price target of $324.46 (represents a 63.37% upside from CRL’s last price of $198.61) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.
CRL Price Target
The average price target for Charles River Laboratories (CRL) is $324.46 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $465.00 to $230.00. This represents a potential 63.37% upside from CRL's last price of $198.61.
CRL Analyst Ratings
According to 11 Wall Street analysts, Charles River Laboratories's rating consensus is 'Buy'. The analyst rating breakdown for CRL stock is 0 'Strong Buy' (0.00%), 7 'Buy' (63.64%), 3 'Hold' (27.27%), 1 'Sell' (9.09%), and 0 'Strong Sell' (0.00%).
Charles River Laboratories Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 08, 2024 | Justin Bowers | Deutsche Bank | $240.00 | $200.34 | 19.80% | 20.84% |
| Jul 10, 2024 | Eric Coldwell | Robert W. Baird | $239.00 | $201.85 | 18.40% | 20.34% |
| Jun 28, 2024 | Luke Sergott | Barclays | $230.00 | $207.35 | 10.92% | 15.80% |
| Jun 06, 2024 | Matthew Sykes | Goldman Sachs | $290.00 | $216.12 | 34.18% | 46.01% |
| May 09, 2024 | Elizabeth Anderson | Evercore ISI | $265.00 | $230.09 | 15.17% | 33.43% |
| Apr 01, 2024 | Elizabeth Anderson | Evercore ISI | $300.00 | $270.95 | 10.72% | 51.05% |
| May 05, 2022 | Donald Hooker | KeyBanc | $300.00 | $257.51 | 16.50% | 51.05% |
| Apr 25, 2022 | - | Wells Fargo | $325.00 | $257.75 | 26.09% | 63.64% |
| Apr 25, 2022 | David Windley | Jefferies | $280.00 | $273.03 | 2.55% | 40.98% |
| Jan 11, 2022 | David Windley | Jefferies | $464.00 | $357.95 | 29.63% | 133.62% |
The latest Charles River Laboratories stock forecast, released on Aug 08, 2024 by Justin Bowers from Deutsche Bank, set a price target of $240.00, which represents a 19.80% increase from the stock price at the time of the forecast ($200.34), and a 20.84% increase from CRL last price ($198.61).
Charles River Laboratories Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 3 | 6 |
| Avg Price Target | - | $236.33 | $260.67 |
| Last Closing Price | $198.61 | $198.61 | $198.61 |
| Upside/Downside | -100.00% | 18.99% | 31.25% |
In the current month, the average price target of Charles River Laboratories stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Charles River Laboratories's last price of $198.61. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 08, 2024 | Deutsche Bank | Buy | Buy | Hold |
| Jun 27, 2024 | Barclays | - | Equal-Weight | Initialise |
| Jun 06, 2024 | Goldman Sachs | - | Buy | Initialise |
| May 13, 2024 | Cowen & Co. | Hold | Hold | Hold |
| May 09, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Apr 01, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Feb 23, 2023 | Guggenheim | - | Buy | Upgrade |
| Jan 12, 2023 | Jefferies | Buy | Hold | Downgrade |
| Nov 09, 2022 | Bank of America Securities | Buy | Reduce | Downgrade |
| Nov 03, 2022 | CFRA | - | Buy | Upgrade |
Charles River Laboratories's last stock rating was published by Deutsche Bank on Aug 08, 2024. The company gave CRL a "Buy" rating, the same as its previous rate.
Charles River Laboratories Financial Forecast
Charles River Laboratories Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.03B | $1.06B | $1.03B | $1.10B | $989.16M | $973.13M | $913.93M | $905.05M | $895.94M | $914.61M | $824.57M | $790.99M | $743.30M |
| Avg Forecast | $1.22B | $1.16B | $1.09B | $1.09B | $1.12B | $1.10B | $1.07B | $1.07B | $1.05B | $1.03B | $1.02B | $1.01B | $982.19M | $977.57M | $1.02B | $992.31M | $991.25M | $1.00B | $1.05B | $986.31M | $1.04B | $970.43M | $995.18M | $910.10M | $888.27M | $906.90M | $880.72M | $798.20M | $756.86M | $716.88M |
| High Forecast | $1.24B | $1.18B | $1.10B | $1.11B | $1.14B | $1.11B | $1.09B | $1.08B | $1.07B | $1.04B | $1.04B | $1.02B | $995.95M | $990.28M | $1.04B | $1.01B | $999.99M | $1.03B | $1.07B | $1.00B | $1.05B | $984.02M | $995.18M | $956.07M | $933.14M | $952.71M | $925.20M | $838.52M | $795.09M | $753.09M |
| Low Forecast | $1.20B | $1.15B | $1.07B | $1.08B | $1.11B | $1.08B | $1.06B | $1.06B | $1.04B | $1.01B | $1.01B | $994.04M | $969.61M | $968.37M | $1.01B | $979.59M | $982.33M | $990.09M | $1.04B | $973.67M | $1.02B | $957.99M | $995.18M | $894.24M | $872.79M | $891.09M | $865.37M | $784.29M | $743.67M | $704.38M |
| # Analysts | 6 | 4 | 4 | 6 | 5 | 4 | 8 | 5 | 3 | 3 | 6 | 3 | 4 | 9 | 6 | 3 | 6 | 12 | 8 | 8 | 5 | 5 | 5 | 3 | 4 | 7 | 4 | 6 | 9 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 1.01% | 1.04% | 1.06% | 1.02% | 0.98% | 1.00% | 1.02% | 0.99% | 1.04% | 1.03% | 1.05% | 1.04% |
Charles River Laboratories's average Quarter revenue forecast for Dec 23 based on 6 analysts is $991.25M, with a low forecast of $982.33M, and a high forecast of $999.99M. CRL's average Quarter revenue forecast represents a -3.45% decrease compared to the company's last Quarter revenue of $1.03B (Sep 23).
Charles River Laboratories EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 5 | 4 | 8 | 5 | 3 | 3 | 6 | 3 | 4 | 9 | 6 | 3 | 6 | 12 | 8 | 8 | 5 | 5 | 5 | 3 | 4 | 7 | 4 | 6 | 9 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $225.49M | $164.94M | $242.49M | $315.13M | $209.09M | $185.42M | $195.58M | $205.38M | $208.41M | $176.66M | $157.53M | $233.58M | $213.72M |
| Avg Forecast | $294.52M | $280.12M | $262.55M | $264.15M | $271.33M | $264.96M | $258.72M | $258.35M | $253.94M | $247.90M | $247.00M | $243.13M | $237.15M | $236.04M | $247.33M | $231.40M | $239.34M | $241.57M | $254.42M | $210.37M | $249.91M | $215.85M | $240.29M | $191.24M | $233.23M | $196.22M | $190.96M | $131.04M | $230.23M | $151.00M |
| High Forecast | $298.65M | $284.04M | $266.23M | $267.84M | $275.12M | $268.67M | $262.34M | $261.96M | $257.49M | $251.37M | $250.46M | $246.53M | $240.47M | $239.11M | $250.79M | $277.68M | $241.45M | $248.70M | $257.98M | $252.44M | $253.41M | $259.01M | $240.29M | $229.49M | $279.88M | $235.47M | $229.16M | $157.25M | $276.27M | $181.20M |
| Low Forecast | $290.75M | $276.53M | $259.19M | $260.76M | $267.85M | $261.56M | $255.40M | $255.03M | $250.68M | $244.72M | $243.83M | $240.01M | $234.11M | $233.82M | $244.16M | $185.12M | $237.19M | $239.06M | $251.16M | $168.29M | $246.71M | $172.68M | $240.29M | $152.99M | $186.59M | $156.98M | $152.77M | $104.83M | $184.18M | $120.80M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.93% | 0.65% | 1.15% | 1.26% | 0.97% | 0.77% | 1.02% | 0.88% | 1.06% | 0.93% | 1.20% | 1.01% | 1.42% |
6 analysts predict CRL's average Quarter EBITDA for Dec 23 to be $239.34M, with a high of $241.45M and a low of $237.19M. This is 6.14% upper than Charles River Laboratories's previous annual EBITDA (Sep 23) of $225.49M.
Charles River Laboratories Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 5 | 4 | 8 | 5 | 3 | 3 | 6 | 3 | 4 | 9 | 6 | 3 | 6 | 12 | 8 | 8 | 5 | 5 | 5 | 3 | 4 | 7 | 4 | 6 | 9 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $87.39M | $97.02M | $103.13M | $187.41M | $96.47M | $109.32M | $93.02M | $139.83M | $103.43M | $88.45M | $61.53M | $143.19M | $102.91M |
| Avg Forecast | $186.12M | $166.57M | $137.15M | $139.43M | $162.80M | $151.98M | $148.00M | $140.73M | $148.87M | $139.09M | $138.99M | $128.95M | $130.68M | $125.52M | $124.13M | $111.32M | $124.53M | $122.20M | $136.79M | $101.20M | $142.33M | $108.01M | $141.95M | $92.00M | $133.60M | $98.19M | $80.31M | $51.98M | $124.19M | $72.61M |
| High Forecast | $189.50M | $169.60M | $139.64M | $141.97M | $165.76M | $154.74M | $150.69M | $143.29M | $151.58M | $141.62M | $141.52M | $131.30M | $133.06M | $127.60M | $126.38M | $133.58M | $129.22M | $129.42M | $139.28M | $121.43M | $144.92M | $129.62M | $141.95M | $110.40M | $160.32M | $117.83M | $96.37M | $62.37M | $149.03M | $87.13M |
| Low Forecast | $183.02M | $163.79M | $134.86M | $137.11M | $160.08M | $149.45M | $145.53M | $138.38M | $146.39M | $136.77M | $136.68M | $126.80M | $128.51M | $122.41M | $122.06M | $89.05M | $117.24M | $120.14M | $134.51M | $80.96M | $139.95M | $86.41M | $141.95M | $73.60M | $106.88M | $78.56M | $64.25M | $41.58M | $99.35M | $58.09M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.72% | 0.71% | 1.02% | 1.32% | 0.89% | 0.77% | 1.01% | 1.05% | 1.05% | 1.10% | 1.18% | 1.15% | 1.42% |
Charles River Laboratories's average Quarter net income forecast for Dec 23 is $124.53M, with a range of $117.24M to $129.22M. CRL's average Quarter net income forecast represents a 42.50% increase compared to the company's last Quarter net income of $87.39M (Sep 23).
Charles River Laboratories SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 5 | 4 | 8 | 5 | 3 | 3 | 6 | 3 | 4 | 9 | 6 | 3 | 6 | 12 | 8 | 8 | 5 | 5 | 5 | 3 | 4 | 7 | 4 | 6 | 9 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $176.11M | $199.76M | $174.85M | $199.64M | $183.71M | $131.71M | $150.03M | $144.11M | $148.57M | $171.50M | $155.73M | $143.03M | $128.29M |
| Avg Forecast | $220.02M | $209.26M | $196.13M | $197.32M | $202.69M | $197.93M | $193.27M | $192.99M | $189.70M | $185.18M | $184.52M | $181.63M | $177.16M | $176.33M | $184.76M | $179.54M | $178.79M | $180.46M | $190.06M | $163.22M | $186.69M | $155.16M | $179.50M | $148.38M | $139.94M | $141.06M | $155.71M | $131.56M | $124.05M | $90.52M |
| High Forecast | $223.10M | $212.19M | $198.88M | $200.09M | $205.53M | $200.70M | $195.98M | $195.69M | $192.36M | $187.78M | $187.10M | $184.17M | $179.64M | $178.62M | $187.35M | $215.45M | $180.37M | $185.78M | $192.72M | $195.86M | $189.30M | $186.20M | $179.50M | $178.05M | $167.93M | $169.27M | $186.86M | $157.87M | $148.86M | $108.62M |
| Low Forecast | $217.20M | $206.58M | $193.62M | $194.79M | $200.09M | $195.39M | $190.79M | $190.52M | $187.27M | $182.81M | $182.15M | $179.30M | $174.89M | $174.67M | $182.40M | $143.63M | $177.19M | $178.59M | $187.62M | $130.57M | $184.30M | $124.13M | $179.50M | $118.70M | $111.95M | $112.85M | $124.57M | $105.24M | $99.24M | $72.41M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.98% | 1.05% | 1.07% | 1.07% | 1.18% | 0.73% | 1.01% | 1.03% | 1.05% | 1.10% | 1.18% | 1.15% | 1.42% |
Charles River Laboratories's average Quarter SG&A projection for Dec 23 is $178.79M, based on 6 Wall Street analysts, with a range of $177.19M to $180.37M. The forecast indicates a 1.52% rise compared to CRL last annual SG&A of $176.11M (Sep 23).
Charles River Laboratories EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 5 | 4 | 8 | 5 | 3 | 3 | 6 | 3 | 4 | 9 | 6 | 3 | 6 | 12 | 8 | 8 | 5 | 5 | 5 | 3 | 4 | 7 | 4 | 6 | 9 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.70 | $1.89 | $2.02 | $3.68 | $1.90 | $2.15 | $1.84 | $2.77 | $2.05 | $1.76 | $1.23 | $2.88 | $2.07 |
| Avg Forecast | $3.59 | $3.21 | $2.65 | $2.69 | $3.14 | $2.93 | $2.85 | $2.71 | $2.87 | $2.68 | $2.68 | $2.49 | $2.52 | $2.42 | $2.39 | $2.06 | $2.40 | $2.36 | $2.64 | $2.59 | $2.75 | $2.50 | $2.74 | $2.72 | $2.43 | $2.58 | $2.38 | $2.19 | $2.11 | $1.80 |
| High Forecast | $3.66 | $3.27 | $2.69 | $2.74 | $3.20 | $2.98 | $2.91 | $2.76 | $2.92 | $2.73 | $2.73 | $2.53 | $2.57 | $2.46 | $2.44 | $2.10 | $2.49 | $2.50 | $2.69 | $2.64 | $2.80 | $2.55 | $2.74 | $2.90 | $2.59 | $2.75 | $2.54 | $2.33 | $2.25 | $1.92 |
| Low Forecast | $3.53 | $3.16 | $2.60 | $2.64 | $3.09 | $2.88 | $2.81 | $2.67 | $2.82 | $2.64 | $2.64 | $2.45 | $2.48 | $2.36 | $2.35 | $2.03 | $2.26 | $2.32 | $2.59 | $2.55 | $2.70 | $2.46 | $2.74 | $2.66 | $2.38 | $2.53 | $2.33 | $2.14 | $2.06 | $1.76 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.72% | 0.72% | 0.78% | 1.34% | 0.76% | 0.79% | 0.68% | 1.14% | 0.79% | 0.74% | 0.56% | 1.37% | 1.15% |
According to 6 Wall Street analysts, Charles River Laboratories's projected average Quarter EPS for Dec 23 is $2.40, with a low estimate of $2.26 and a high estimate of $2.49. This represents a 41.29% increase compared to CRL previous annual EPS of $1.70 (Sep 23).
Charles River Laboratories Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| GH | Guardant Health | $26.79 | $57.27 | 113.77% | Buy |
| CRL | Charles River Laboratories | $198.61 | $324.46 | 63.37% | Buy |
| ILMN | Illumina | $129.18 | $200.82 | 55.46% | Buy |
| LH | Laboratory Corporation of America | $221.13 | $287.00 | 29.79% | Buy |
| MEDP | Medpace | $351.67 | $444.20 | 26.31% | Buy |
| IQV | IQVIA | $238.70 | $269.43 | 12.87% | Buy |
| CDNA | CareDx | $28.87 | $31.00 | 7.38% | Buy |
| A | Agilent | $137.31 | $144.90 | 5.53% | Buy |
| ICLR | ICON Public Limited Company | $300.00 | $307.63 | 2.54% | Buy |
| RVTY | Revvity | $122.03 | $123.83 | 1.48% | Hold |
| WAT | Waters | $325.86 | $325.00 | -0.26% | Buy |
| MTD | Mettler-Toledo | $1.38K | $1.36K | -1.35% | Hold |
| IDXX | IDEXX Laboratories | $500.55 | $479.75 | -4.16% | Buy |
CRL Forecast FAQ
Is Charles River Laboratories a good buy?
Yes, according to 11 Wall Street analysts, Charles River Laboratories (CRL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 63.64% of CRL's total ratings.
What is CRL's price target?
Charles River Laboratories (CRL) average price target is $324.46 with a range of $230 to $465, implying a 63.37% from its last price of $198.61. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Charles River Laboratories stock go up soon?
According to Wall Street analysts' prediction for CRL stock, the company can go up by 63.37% (from the last price of $198.61 to the average price target of $324.46), up by 134.13% based on the highest stock price target, and up by 15.80% based on the lowest stock price target.
Can Charles River Laboratories stock reach $300?
CRL's average twelve months analyst stock price target of $324.46 supports the claim that Charles River Laboratories can reach $300 in the near future.
What are Charles River Laboratories's analysts' financial forecasts?
Charles River Laboratories's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $4.36B (high $4.42B, low $4.31B), average EBITDA is $1.05B (high $1.07B, low $1.04B), average net income is $603.5M (high $614.48M, low $593.44M), average SG&A $786.88M (high $797.9M, low $776.79M), and average EPS is $11.64 (high $11.85, low $11.45). CRL's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $4.56B (high $4.63B, low $4.5B), average EBITDA is $1.1B (high $1.12B, low $1.09B), average net income is $629.26M (high $640.71M, low $618.78M), average SG&A $822.73M (high $834.25M, low $812.19M), and average EPS is $12.14 (high $12.36, low $11.93).
Did the CRL's actual financial results beat the analysts' financial forecasts?
Based on Charles River Laboratories's last annual report (Dec 2023), the company's revenue was $4.13B, beating the average analysts forecast of $4.03B by 2.42%. Apple's EBITDA was $617.26M, missing the average prediction of $945.7M by -34.73%. The company's net income was $480.37M, missing the average estimation of $484.72M by -0.90%. Apple's SG&A was $747.86M, beating the average forecast of $712.53M by 4.96%. Lastly, the company's EPS was $9.38, missing the average prediction of $9.99 by -6.07%. In terms of the last quarterly report (Sep 2023), Charles River Laboratories's revenue was $1.03B, beating the average analysts' forecast of $1B by 2.61%. The company's EBITDA was $225.48M, missing the average prediction of $241.57M by -6.66%. Charles River Laboratories's net income was $87.39M, missing the average estimation of $122.2M by -28.49%. The company's SG&A was $176.11M, missing the average forecast of $180.46M by -2.41%. Lastly, the company's EPS was $1.7, missing the average prediction of $2.36 by -27.88%